Don't allow Congress to let you go blind!: |
Reverse cataracts with a simple-and safe-eyedrop formula
By Jonathan V. Wright, M.D.
You might not think of cataracts as a political issue, but thanks to Congress it has become one. Since Congress has allowed the FDA to ignore the 1st Amendment and suppress the release of truthful scientific research about natural products, I continue to encounter individuals with early to medium-stage cataracts who have no idea that it's usually possible to reverse or stop the progress of their conditions and often improve their vision with a safe, natural, scientifically researched eyedrop.
Of course, if a patent medicine "approved" at an enormous price by los Federales reversed cataracts, it'd be all over TV, radio, newspapers, billboards, and everywhere else. But being a patent medicine, it would also cost hundreds of dollars a month and drive up the cost of "Mediocare" and other programs for senior citizens even further. And, like most patent medications, it would very likely have serious side effects for some users, which would be denied for as long as possible before the product was removed from the market, followed by Congressional hearings, miscellaneous hand-wringing, and so on.
But I digress.
Since the natural cataract-reversing eyedrop became available, the majority of the people who have been using it are very pleased with the results. But since the media and los Federales certainly won't be filling you in on the details anytime soon, it's time to take matters into our own hands and review the randomized, placebo-controlled studies that helped prove that N-acetylcarnosine can reverse cataracts in many cases.
Up to 100 percent better vision in just 6 months
In a study published in 2002, researchers enrolled 49 cataract patients.1 Twenty-six of the participants used eyedrops containing 1 percent N-acetylcarnosine twice daily, 13 research volunteers used a placebo eyedrop twice daily, and the other 10 individuals got no eyedrops at all.
The research team evaluated all the participants every two months for the first six months of the trial, then at six-month intervals for the next two years. During the evaluations, they ran tests for visual acuity and glare. They also took measurements of the participants' cataracts by stereocinematographic slit-images and retro-illumination examination of the lens, and digital analysis of lens images displayed light scattering and absorbing centres in two- and three-dimensional scales. (Just a quick disclaimer: I'm not an ophthalmologist and don't know how to do or interpret these tests, but it's important to mention them for those who are capable and in case you show this to your own eye doctor!)
After six months, 90 percent of the N-acetylcarnosine-treated eyes showed improvement ranging from 7 percent to 100 percent in visual acuity, and 88.9 percent showed a 27 to 100 percent improvement in glare sensitivity. The technical studies noted above found fewer areas of posterior subcapsular lens opacity and 41.5 percent of the N-acetylcarnosine treated eyes had improvement in the visual image seen. According to the researchers, the degree of change in visual image between the N-acetylcarnosine group and the two control groups (placebo and no treatment) was statistically very significant. And what makes these results even more impressive is that the improvements were sustained over the entire two-year study period not a single patient taking the N-acetylcarnosine eyedrops had any worsening of vision!
By contrast, the control groups showed significant worsening after both six and 24 months. All the patients taking the N-acetylcarnosine eyedrops tolerated them well, and there were no reports of side effects in the eyes or anywhere else in the body.
Better vision + less glare = safer driving conditions
In 2004 a member of the same research group published another randomized, double-blind, placebo-controlled study comparing the effects of 1 percent N-acetylcarnosine eyedrops to placebo on glare sensitivity in 65 older automobile drivers with cataracts in one or both eyes and 72 older drivers who had no cataracts.2
After four months, the placebo group reported a gradual worsening of glare sensitivity, with minimal changes in visual acuity. But the N-acetylcarnosine groups reported a statistically significant improvement in glare sensitivity and visual acuity over those same four months. As in the prior research, the N-acetylcarnosine eyedrops were well-tolerated in almost all patients, and there were no reports of adverse effects.
No reason not to try
So far, these two studies are the only controlled research on N-acetylcarnosine and cataract reversal, so from a strict "scientific research" point of view, the classic "more research is needed" line definitely applies.
But since N-acetylcarnosine is totally unpatentable, it will likely be decades before "scientifically adequate" research is actually done. And, unfortunately you're more likely to become double-blind (from cataracts) before enough double-blind research is completed to convince "mainstream" medicine!
Still, even though the research is technically in the "preliminary" stages, if you have early or moderate cataracts, you might want to consider trying N-acetylcarnosine anyway, for two important reasons: It may work for you, and it's safe. None of the individuals I have worked with have had even minor side effects, and no adverse effects have been discovered by researchers.
Of course, as safe as N-acetylcarnosine is, it's always a good idea to have your eyes checked before starting and perhaps six months to a year later, if for no other reason than to help you decide whether to continue using the eyedrops if you haven't noticed a significant difference by then. (But keep in mind that since cataracts naturally get worse over time, if yours stay the same, that's still progress - although obviously not as much as actual reversal would be.)
The version of N-acetylcarnosine eyedrops tested in the studies is called "Can-C" and is sold through the Tahoma Clinic Dispensary and on-line by International Anti-aging Systems (www.anti-agingsystems.com).
(Note: N-acetylcarnosine is not the same as N-acetylcarnitine, another very useful substance with entirely different actions.)
Although I am of course affiliated with the Tahoma Clinic Dispensary, I am not associated with the researchers, manufacturers, or other distributors of "Can-C" or other N-acetylcarnosine products. JVW
1 Babizhayev MA, et al. "Efficacy of N-acetylcarnosine in the treatment of cataracts," Drugs R D 2002; 3(2): 87-103
2 Babizhayev MA. "Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops," Rejuvenation Res 2004; 7(3): 186-198
This article was published in the July, 2008 issue of the Dr. Jonathan V. Wright's Clinical Nutrition & Healing newsletter, and is presented here with permission.